Indocyanine Green Acid Form

Summary

Indocyanine Green Acid Form (CHEMBL1201304) is an approved small molecule (ATC V04CX01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: V04CX01
• Clinical trials: 139
• Chemistry: 753 Da · C43H48N2O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201304
Name	Indocyanine Green Acid Form
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	145948239
ATC	V04CX01
Molecular formula	C43H48N2O6S2
Molecular weight	753
InChIKey	BDBMLMBYCXNVMC-UHFFFAOYSA-N

SMILES: CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)O)/C=C\C=C\C=C\C=C/4\C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C

IUPAC name: 4-[(2Z)-2-[(2E,4E,6Z)-7-[1,1-dimethyl-3-(4-sulfobutyl)benzo[e]indol-3-ium-2-yl]hepta-2,4,6-trienylidene]-1,1-dimethylbenzo[e]indol-3-yl]butane-1-sulfonate

Also known as: Crysta-lyn 551522, Indocyanine green acid form, NK 5078, NK-5078, INDOCYANINE GREEN ACID FORM, indocyanine green

Parent form; salt/anhydrous children: CHEMBL1646

Patent coverage: 3,440 distinct patent families (7,044 SureChEMBL compound mentions), from 4 matched compound structure(s). One matched structure accounts for 7,034 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 39 (assay-derived). Sample: Vasopressin V1a receptor, 5-hydroxytryptamine receptor 3A, Cholecystokinin receptor type A, Alpha-2C adrenergic receptor, Histamine H2 receptor, Alpha-2B adrenergic receptor, Equilibrative nucleoside transporter 1, D(1A) dopamine receptor, Thromboxane A2 receptor, Progesterone receptor.

Bioactivity

ChEMBL activities: 22 potent at pChembl ≥ 5 of 39 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
NR1I2	6	AC50	1000	nM	CHEMBL_ACT_25223837
PDE4D	5.64	AC50	2300	nM	CHEMBL_ACT_25185439
ADORA3	5.52	AC50	3000	nM	CHEMBL_ACT_25134319
PGR	5.47	AC50	3400	nM	CHEMBL_ACT_25222216
SLC6A2	5.28	AC50	5200	nM	CHEMBL_ACT_25145109
SLC6A3	5.25	AC50	5600	nM	CHEMBL_ACT_25124060
HTR2C	5.25	AC50	5600	nM	CHEMBL_ACT_25131917
KCNH2	5.19	AC50	6500	nM	CHEMBL_ACT_25118028
P15207	5.17	AC50	6800	nM	CHEMBL_ACT_25232372
ADRA2B	5.16	AC50	6900	nM	CHEMBL_ACT_25143812
AVPR1A	5.11	AC50	7700	nM	CHEMBL_ACT_25162226
HRH1	5.08	AC50	8300	nM	CHEMBL_ACT_25212624
PTGS2	5.07	AC50	8600	nM	CHEMBL_ACT_25166296
DRD2	5.06	AC50	8800	nM	CHEMBL_ACT_25140446
DRD3	5.06	AC50	8700	nM	CHEMBL_ACT_25193637
AGTR1	5.05	AC50	9000	nM	CHEMBL_ACT_25177098
CHRM1	5.04	AC50	9200	nM	CHEMBL_ACT_25135566
CCKBR	5.04	AC50	9200	nM	CHEMBL_ACT_25171518
ADRB1	5.03	AC50	9400	nM	CHEMBL_ACT_25121885
CNR1	5.03	AC50	9300	nM	CHEMBL_ACT_25231699
ADRA2C	5.01	AC50	9700	nM	CHEMBL_ACT_25147988
OPRD1	5.01	AC50	9700	nM	CHEMBL_ACT_25154178

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 139.

Phase distribution

Phase	Trials
Not specified	50
PHASE2	25
PHASE4	21
PHASE1	18
EARLY_PHASE1	9
PHASE1/PHASE2	7
PHASE3	6
PHASE2/PHASE3	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06002906	PHASE4	ACTIVE_NOT_RECRUITING	The Use of Indocyanine Green to Visualize Blood Flow to the Gastrojejunostomy During Bariatric Surgery.
NCT06398028	PHASE4	RECRUITING	The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound.
NCT06871787	PHASE4	NOT_YET_RECRUITING	Near-Infrared Fluorescence Imaging With Indocyanine Green to Evaluate Bowel Anastomoses in Gynecologic Oncology Surgery
NCT07315828	PHASE4	RECRUITING	Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery
NCT07315841	PHASE4	RECRUITING	Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery
NCT02781259	PHASE4	UNKNOWN	Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer
NCT03080558	PHASE4	UNKNOWN	Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving
NCT03155464	PHASE4	WITHDRAWN	Intraoperative ICG for Systemic Sclerosis
NCT03584633	PHASE4	COMPLETED	Effect of Exercise on Indocyanine Green (ICG) Lymphography Imaging
NCT03969108	PHASE4	COMPLETED	Diagnostic Accuracy Study of Indocyanine Green for Parathyroid Perfusion Assessment
NCT04012476	PHASE4	UNKNOWN	Determination of Parathyroid Function by Fluorescence With Indocyanine Green (ICG) After Total Thyroidectomy
NCT04591028	PHASE4	WITHDRAWN	A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
NCT04624841	PHASE4	UNKNOWN	Indocyanine Green to Visualize Critical View of Safety During Laparoscopic Cholecystectomy for Acute Cholecystitis
NCT04854018	PHASE4	COMPLETED	Indo-cyanine Green (ICG) in Paediatric Oncology MIS
NCT04882618	PHASE4	UNKNOWN	Use of Indocyanine Green During Pelvic Lymph Node Dissection in Prostate Cancer.
NCT05332405	PHASE4	WITHDRAWN	SPY Angiography To Assist With Ulnar Nerve Transposition at the Elbow
NCT05354856	PHASE4	TERMINATED	The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
NCT05709548	PHASE4	UNKNOWN	Use of Indocyanine Green in Acute Cholecystitis
NCT06164392	PHASE4	WITHDRAWN	Evaluation of Neuroma Perfusion with Indocyanine Green Fluorescence Angiography
NCT06169735	PHASE4	TERMINATED	Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
NCT06629415	PHASE4	COMPLETED	Using Indocyanine Green (ICG) to Outline Biliary Tree During Laparoscopic Cholecystectomy
NCT04611997	PHASE3	ACTIVE_NOT_RECRUITING	IGG Using in Laparoscopic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
NCT04878094	PHASE3	RECRUITING	A Study of Intra-operative Imaging in Women With Ovarian Cancer
NCT01083004	PHASE3	UNKNOWN	Brilliant Blue Versus Indocyanine Green
NCT02279108	PHASE3	COMPLETED	Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer
NCT02850783	PHASE2/PHASE3	COMPLETED	SLN in Colon Cancer Using a Multimodal Tracer
NCT02997553	PHASE3	COMPLETED	Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery
NCT04857346	PHASE2/PHASE3	COMPLETED	Antimicrobial Photodynamic Therapy in Chronic Periodontitis and Diabetes Mellitus
NCT04904081	PHASE3	UNKNOWN	Feasibility of Use of Indocyanine Green in Pediatric Colorectal Surgery
NCT05926856	PHASE2/PHASE3	COMPLETED	High Quality Fluorescent Cholangiography
NCT04723810	PHASE1/PHASE2	RECRUITING	TumorGlow Intraoperative Molecular Imaging (IMI)
NCT04752137	PHASE2	RECRUITING	Intraoperative Tumor Margin Identification With ICG Dye Imaging
NCT04842162	PHASE2	RECRUITING	Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
NCT04973475	PHASE2	NOT_YET_RECRUITING	Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer
NCT06327490	PHASE2	RECRUITING	A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT00540982	PHASE1/PHASE2	COMPLETED	Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
NCT01662752	PHASE2	COMPLETED	Lymphatic Mapping for Sentinel Node Identification and Analysis
NCT01771666	PHASE2	COMPLETED	Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer
NCT01993576	PHASE1/PHASE2	COMPLETED	ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.
NCT02027818	PHASE2	COMPLETED	Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).